Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.

How the vaccine safeguards at-risk babies

RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can vary from causing mild cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”

The pregnancy vaccine operates by stimulating the mother’s immune system to generate defence proteins, which are then passed to the foetus through the placenta. This mother-derived protection provides newborns with immediate protection from the moment of birth, exactly when they are most vulnerable to RSV. The latest research demonstrates that protection reaches nearly 85 per cent when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence suggesting that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson recommends pregnant women to have the vaccine at the recommended time, whilst noting that protection remains possible even if administered later in the third trimester.

• Nearly 85 per cent coverage when vaccinated 4 weeks before birth
• Maternal antibodies passed through placenta safeguard newborns from day one
• Protection possible with two-week gap before early delivery
• Vaccination during the third trimester still provides significant infant protection

Persuasive evidence from recent research

The efficacy of the RSV vaccine administered during pregnancy has been demonstrated through a comprehensive study undertaken in England, analysing data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that half-year window, providing strong and reliable data of the vaccine’s real-world impact. The study’s results have been endorsed by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The breadth of this investigation offers healthcare professionals and prospective parents with assurance in the vaccine’s established performance across varied populations and settings.

The results paint a striking picture of the vaccine’s protective effectiveness. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not received the vaccination. This clear distinction underscores the vaccine’s essential role in protecting against serious illness in newborns. The reduction in hospital admissions above 80 per cent represents a major public health success, possibly preventing thousands of infants from experiencing the alarming and potentially severe symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.

Research approach and coverage

The research reviewed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish direct comparisons of RSV infection rates and hospitalisations. The sizeable sample and thorough nature of the data gathering ensured that findings were statistically significant and indicative of the general population, rather than isolated cases or small subgroups.

The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology measured actual clinical results rather than controlled laboratory conditions, providing real-world data of how the vaccine performs when administered across different clinical contexts and patient circumstances throughout the final three months of pregnancy.

Learning about RSV and the risks

Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.

The infection produces inflammation deep within the lungs and airways, making it perilously hard for infected babies to feed and breathe effectively. Parents commonly see their babies struggling visibly, their chests heaving as they try to pull enough air into their damaged lungs. Whilst most newborns recover with supportive care, a small but significant proportion perish from respiratory syncytial virus complications yearly, making prevention through vaccination a essential public health imperative for defending the youngest and most at-risk individuals in the population.

• RSV causes lung inflammation, leading to serious respiratory problems in babies
• Half of all newborns contract the virus in their first few months of life
• Symptoms span from minor cold-like symptoms to serious chest infections that threaten life needing hospital treatment
• Over 20,000 UK infants require serious hospital care for RSV each year
• A small number of babies die from RSV complications each year in the UK

Adoption rates and professional guidance

Since the RSV vaccine programme commenced in 2024, health officials have highlighted the value of pregnant women getting their jab at the ideal time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that timing matters greatly for guaranteeing newborns benefit from the strongest possible immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery delivers approximately 85% protection, experts recommend women to receive their vaccine as early as possible from 28 weeks of pregnancy onwards to enhance the antibodies transferred to their babies via the placenta.

The guidance from health authorities remains clear: pregnant women should make a priority of vaccination during their final three months, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has provided reassurance to expectant mothers that protection remains still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This flexible approach recognises the realities of pregnancy and childbirth whilst ensuring strong safeguarding for vulnerable newborns during their most critical early months when RSV poses the greatest risk of severe infection.

Regional variations in vaccine uptake

Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have differed across various areas and NHS trusts. Some areas have achieved greater immunisation rates among eligible pregnant women, whilst others remain focused to increase awareness and access to the jab. These regional differences demonstrate variations in healthcare infrastructure, engagement approaches, and local engagement efforts, though the overall statistics shows consistently strong protection irrespective of geographical location.

• NHS trusts rolling out multiple messaging strategies to engage with women during pregnancy
• Geographic variations in vaccination coverage levels in different parts of England require targeted improvement
• Community health services adapting programmes to suit community needs and circumstances

Real-world impact and parental perspectives

The vaccine’s outstanding effectiveness translates into tangible benefits for families throughout the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV prior to the launch of this safeguarding intervention, the 80% decrease in admissions means thousands of infants protected against severe infection. Parents no more face the troubling prospect of seeing their babies gasping for air or labour to feed, symptoms that characterise severe RSV infections. The vaccine has fundamentally shifted the picture of neonatal respiratory health, offering expectant mothers a proactive tool to protect their most at-risk babies during those critical early months.

For families like that of Malachi, whose serious RSV infection caused severe brain damage, the vaccine’s introduction carries significant emotional significance. His mother’s advocacy for the jab underscores the life-altering consequences that vaccine-preventable disease can inflict on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such significant complications—hospital stay, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to women in pregnancy navigating their third trimester, transforming what was once an unavoidable seasonal threat into a controllable health concern.